Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile
Stockholm, Sweden October 31, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has presented the latest findings for lecanemab (Leqembi®) at the Clinical Trials on Alzheimer’s Disease, CTAD, congress, held in Madrid, Spain, and virtually, October 29 to November 1. Three-year data show that lecanemab continues to give increased patient benefit for patients with early Alzheimer’s disease, expanding approximately 1 point on CDR-SB compared to the ADNI[1]-population, with maintained safety profile. In addition, data show that 46% of patients who had low levels of brain
Fazer has ambitious emission reduction targets in line with its commitment to the international SBT (Science Based Targets) initiative. As part of its emission reduction targets, Fazer will electrify steam production at Lappeenranta confectionery factory. With electrification, the factory's carbon dioxide emissions will be reduced by approximately 90 per cent annually, and the emissions of Fazer Group by over 10 per cent. The reduction is due to the change of the energy source for steam production to one with less emissions. Furthermore, significant energy savings are created as heat is